Goldman G A, Tadir Y, Ovadia J, Fisch B
Department of Obstetrics and Gynecology, Beilinson Medical Center, Sackler School of Medicine, Tel-Aviv University, Petah-Tikva, Israel.
J Assist Reprod Genet. 1993 Jan;10(1):78-81. doi: 10.1007/BF01204445.
The population exposed to repeated cycles of gonadotropin-releasing hormone analogue treatment before in vitro fertilization is growing rapidly. Sex steroids have been shown to induce changes in carbohydrate metabolism. In view of the effect of gonadotropin-releasing hormone analogues on sex steroid levels, it seems of interest to investigate carbohydrate metabolism following treatment with these compounds.
Our purpose was to assess possible changes in glucose tolerance following administration of the long-acting gonadotropin-releasing hormone and analogue, D-Trp6 LH-RH.
A 3-hr oral glucose tolerance test with 100 g glucose was performed on all patients, before and after 6 weeks of treatment.
No significant changes in either glucose tolerance or insulin levels following treatment with D-Trp6 LH-RH were demonstrated in the group of 25 women investigated.
With respect to carbohydrate metabolism, D-Trp6 LH-RH may safely be administered to healthy women. Further studies are still required to assess the safety of this GnRH analogue when treating potentially diabetic and diabetic patients.
在体外受精前接受促性腺激素释放激素类似物反复治疗周期的人群正在迅速增加。已表明性类固醇会诱导碳水化合物代谢发生变化。鉴于促性腺激素释放激素类似物对性类固醇水平的影响,研究这些化合物治疗后的碳水化合物代谢似乎很有意义。
我们的目的是评估给予长效促性腺激素释放激素及其类似物D-色氨酸6促黄体生成素释放激素(D-Trp6 LH-RH)后葡萄糖耐量的可能变化。
对所有患者在治疗前和治疗6周后进行了一次口服100克葡萄糖的3小时葡萄糖耐量试验。
在接受调查的25名女性组中,未显示用D-Trp6 LH-RH治疗后葡萄糖耐量或胰岛素水平有显著变化。
就碳水化合物代谢而言,D-Trp6 LH-RH可安全地给予健康女性。在治疗潜在糖尿病患者和糖尿病患者时,仍需要进一步研究来评估这种促性腺激素释放激素类似物的安全性。